Literature DB >> 27965304

Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules.

Keiichiro Okuhira1, Takuji Shoda1, Risa Omura1, Nobumichi Ohoka1, Takayuki Hattori1, Norihito Shibata1, Yosuke Demizu1, Ryo Sugihara1, Asato Ichino1, Haruka Kawahara1, Yukihiro Itoh1, Minoru Ishikawa1, Yuichi Hashimoto1, Masaaki Kurihara1, Susumu Itoh1, Hiroyuki Saito1, Mikihiko Naito2.   

Abstract

Development of novel small molecules that selectively degrade pathogenic proteins would provide an important advance in targeted therapy. Recently, we have devised a series of hybrid small molecules named SNIPER (specific and nongenetic IAP-dependent protein ERaser) that induces the degradation of target proteins via the ubiquitin-proteasome system. To understand the localization of proteins that can be targeted by this protein knockdown technology, we examined whether SNIPER molecules are able to induce degradation of cellular retinoic acid binding protein II (CRABP-II) proteins localized in subcellular compartments of cells. CRABP-II is genetically fused with subcellular localization signals, and they are expressed in the cells. SNIPER(CRABP) with different IAP-ligands, SNIPER(CRABP)-4 with bestatin and SNIPER(CRABP)-11 with MV1 compound, induce the proteasomal degradation of wild-type (WT), cytosolic, nuclear, and membrane-localized CRABP-II proteins, whereas only SNIPER(CRABP)-11 displayed degradation activity toward the mitochondrial CRABP-II protein. The small interfering RNA-mediated silencing of cIAP1 expression attenuated the knockdown activity of SNIPER(CRABP) against WT and cytosolic CRABP-II proteins, indicating that cIAP1 is the E3 ligase responsible for degradation of these proteins. Against membrane-localized CRABP-II protein, cIAP1 is also a primary E3 ligase in the cells, but another E3 ligase distinct from cIAP2 and X-linked inhibitor of apoptosis protein (XIAP) could also be involved in the SNIPER(CRABP)-11-induced degradation. However, for the degradation of nuclear and mitochondrial CRABP-II proteins, E3 ligases other than cIAP1, cIAP2, and XIAP play a role in the SNIPER-mediated protein knockdown. These results indicate that SNIPER can target cytosolic, nuclear, membrane-localized, and mitochondrial proteins for degradation, but the responsible E3 ligase is different, depending on the localization of the target protein.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27965304     DOI: 10.1124/mol.116.105569

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

Review 1.  Targeted Protein Degradation: from Chemical Biology to Drug Discovery.

Authors:  Philipp M Cromm; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-06-22       Impact factor: 8.116

2.  Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation.

Authors:  Kenichiro Shimokawa; Norihito Shibata; Tomoya Sameshima; Naoki Miyamoto; Osamu Ujikawa; Hiroshi Nara; Nobumichi Ohoka; Takayuki Hattori; Nobuo Cho; Mikihiko Naito
Journal:  ACS Med Chem Lett       Date:  2017-09-14       Impact factor: 4.345

3.  Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.

Authors:  Norihito Shibata; Naoki Miyamoto; Katsunori Nagai; Kenichiro Shimokawa; Tomoya Sameshima; Nobumichi Ohoka; Takayuki Hattori; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  Cancer Sci       Date:  2017-06-19       Impact factor: 6.716

Review 4.  Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs.

Authors:  Minoru Ishikawa; Shusuke Tomoshige; Yosuke Demizu; Mikihiko Naito
Journal:  Pharmaceuticals (Basel)       Date:  2020-04-21

5.  Critical role of mitochondrial ubiquitination and the OPTN-ATG9A axis in mitophagy.

Authors:  Koji Yamano; Reika Kikuchi; Waka Kojima; Ryota Hayashida; Fumika Koyano; Junko Kawawaki; Takuji Shoda; Yosuke Demizu; Mikihiko Naito; Keiji Tanaka; Noriyuki Matsuda
Journal:  J Cell Biol       Date:  2020-09-07       Impact factor: 10.539

Review 6.  Major Advances in Targeted Protein Degradation: PROTACs, LYTACs, and MADTACs.

Authors:  Shanique Alabi; Craig Crews
Journal:  J Biol Chem       Date:  2021-04-08       Impact factor: 5.157

7.  Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.

Authors:  Shuiliang Yu; Lei Wang; Danian Che; Mei Zhang; Ming Li; Mikihiko Naito; Wei Xin; Lan Zhou
Journal:  J Exp Clin Cancer Res       Date:  2022-03-08

8.  Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.

Authors:  Norihito Shibata; Kenichiro Shimokawa; Katsunori Nagai; Nobumichi Ohoka; Takayuki Hattori; Naoki Miyamoto; Osamu Ujikawa; Tomoya Sameshima; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  Sci Rep       Date:  2018-09-10       Impact factor: 4.379

Review 9.  The PROTAC technology in drug development.

Authors:  Yutian Zou; Danhui Ma; Yinyin Wang
Journal:  Cell Biochem Funct       Date:  2019-01-02       Impact factor: 3.685

Review 10.  Light-Controllable PROTACs for Temporospatial Control of Protein Degradation.

Authors:  Jing Liu; Yunhua Peng; Wenyi Wei
Journal:  Front Cell Dev Biol       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.